Elisabetta Munzone
European Institute of Oncology · European Istitute of Oncology · European Institute of Oncology, Milano
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Elisabetta Munzone as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:31 UTC. Open this list on ClinicalTrials.gov
- N/ANCT07049133 · Toxicity Markers to Trastuzumab-Deruxtecan (T-DXd) In Patients With Advanced Breast CancerEuropean Institute of Oncology · recruiting · Metastatic Breast Cancer · principal investigator
- Ph2NCT06690840 · Atezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer PatientsEuropean Institute of Oncology · recruiting · Triple Negative Breast Cancer · principal investigator
- Ph2NCT05896566 · A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast CancerETOP IBCSG Partners Foundation · completed · Breast Cancer · study chair
- Ph3NCT03820830 · Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast CancerETOP IBCSG Partners Foundation · active not recruiting · Breast Cancer Recurrent · study chair
- N/ANCT03712696 · Efficacy and Safety of DIGNICAP™ SystemEuropean Institute of Oncology · completed · Breast Cancer, Chemotherapy-induced Alopecia · principal investigator
- Ph2NCT03712956 · CAELYX® as Adjuvant Treatment in Early Stage Luminal B Breast Cancer BREAST CANCEREuropean Institute of Oncology · unknown · Breast Cancer · principal investigator
- Ph2NCT02954055 · MEtronomic TrEatment Option in Advanced bReast cAncerETOP IBCSG Partners Foundation · completed · Breast Cancer · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:31 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:31 UTC. The ranking covers the 200 most relevant of 31 PubMed records, and a shared surname and initials can bring in a namesake. All 31 on PubMed
- 523 citationsRCR 15.6
- Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines.J Natl Cancer Inst · 1995162 citationsRCR 5.0
- Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00.Breast Cancer Res Treat · 2016100 citationsRCR 3.0
- A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma.Br J Cancer · 200972 citationsRCR 1.8
- Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy.Breast Cancer Res · 200661 citationsRCR 1.2
- CDK12 promotes tumorigenesis but induces vulnerability to therapies inhibiting folate one-carbon metabolism in breast cancer.Nat Commun · 202241 citationsRCR 2.6
- Paclitaxel (Taxol) efficacy in patients with advanced breast cancer resistant to anthracyclines.Semin Oncol · 199439 citationsRCR 1.4
- 38 citationsRCR 2.6
- Safety and efficacy study of metronomic vinorelbine, cyclophosphamide plus capecitabine in metastatic breast cancer: A phase II trial.Cancer Lett · 201737 citationsRCR 1.2
- Synergistic activity of oxaliplatin and 5-fluorouracil in patients with metastatic colorectal cancer with progressive disease while on or after 5-fluorouracil.Am J Clin Oncol · 199836 citationsRCR 0.6